8-K: Shareholders Approve Key Corporate Actions Including Reverse Stock Split

Shareholders have approved the election of directors, auditor ratification, and critical proposals for warrant issuances and a reverse stock split, providing the Board flexibility for future capital structure adjustments.

Summary

• Shareholders elected Mary Fisher and Andrew Sandler M.D. as Class I directors to hold office for a term of three years.
• The appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
• The proposal to approve the issuance of shares underlying warrants from a January 21, 2025 Securities Purchase Agreement and a September 10, 2024 Engagement Letter, potentially exceeding 20% of outstanding common stock, was approved.
• The proposal to approve the issuance of shares underlying warrants from a March 27, 2025 Inducement Letter and the Engagement Letter, potentially exceeding 20% of outstanding common stock, was approved.
• An amendment to the Certificate of Incorporation to effect a reverse stock split, with a ratio ranging from one-for-two (1:2) to one-for-thirty (1:30) at the Board's discretion, was approved.
• The proposal to adjourn the Annual Meeting if there were insufficient votes for the Issuance, Inducement, and/or Reverse Stock Split Proposals was also approved.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as all proposed corporate actions, including critical measures like the reverse stock split and warrant issuances, were approved by shareholders. This provides the company with necessary flexibility for capital structure and Nasdaq compliance. However, the need for a reverse stock split itself can be seen as a negative indicator of past performance, tempering overall positive sentiment.

Positives

• All six proposals presented at the Annual Meeting were approved by stockholders, indicating strong shareholder support for management's strategic initiatives.
• The election of two Class I directors, Mary Fisher and Andrew Sandler M.D., ensures continuity in governance.
• The ratification of Baker Tilly US, LLP as the independent auditor provides financial oversight stability.
• Approval of warrant issuances allows the company to fulfill obligations related to prior financing activities.
• Approval of the reverse stock split provides the Board with flexibility to adjust the capital structure, which can be crucial for maintaining Nasdaq listing compliance.

Negatives

• A reverse stock split, while approved, can sometimes be perceived negatively by investors as it often follows a significant decline in share price and may not guarantee long-term price appreciation.
• The approval of warrant issuances, particularly those exceeding 20% of outstanding common stock, implies potential future dilution for existing shareholders.

Risks

• Potential dilution of existing shareholders due to the issuance of shares underlying warrants.
• Risk of negative investor perception or continued share price decline following a reverse stock split, despite its approval.
• The need for a reverse stock split often indicates a low share price, which carries the risk of delisting from Nasdaq if compliance requirements are not met.

Future Outlook

The approval of the reverse stock split provides the Board of Directors with the authority to implement this action at a future date, with the exact ratio to be determined by the Board. This action is typically undertaken to increase the per-share trading price and maintain compliance with exchange listing requirements.

Management Comments

• Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DERMATA THERAPEUTICS, INC. Dated: July 15, 2025 By: /s/ Gerald T. Proehl Gerald T. Proehl Chief Executive Officer

Industry Context

For small-cap biotechnology companies like Dermata Therapeutics, Inc., obtaining shareholder approval for actions such as warrant issuances and reverse stock splits is a common practice. Warrant issuances are often part of financing rounds to raise capital, while reverse stock splits are frequently used to increase share price to meet minimum bid price requirements for continued listing on exchanges like Nasdaq, which is critical for maintaining investor visibility and liquidity.

Comparison to Industry Standards

• The approval of a reverse stock split is a common strategy employed by small-cap biotechnology companies, similar to those like Athersys, Inc. (ATHX) or Sorrento Therapeutics, Inc. (SRNEQ) in the past, to avoid delisting from major exchanges due to low share price.
• The issuance of warrants as part of financing agreements is a standard practice in the biotech industry to attract investors, comparable to deals seen with companies like Cassava Sciences, Inc. (SAVA) or Vaxart, Inc. (VXRT) during their capital raises.
• The election of directors and ratification of auditors are standard corporate governance procedures for all publicly traded companies, aligning with practices across the S&P 500 and Nasdaq-listed firms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the election of directors, potential dilution from warrant issuances, and the upcoming reverse stock split which will reduce the number of shares outstanding while increasing the per-share price.
• Investors: The approvals provide clarity on the company's immediate corporate actions and capital structure plans, which may influence investment decisions.
• Management/Board: Granted authority to proceed with key strategic actions, including the reverse stock split.
• Nasdaq: The reverse stock split is likely intended to maintain compliance with Nasdaq listing rules, which is crucial for the company's public trading status.

Next Steps

• The Board of Directors will determine the exact ratio for the approved reverse stock split.
• The company will proceed with the issuance of shares underlying the approved warrants as per the terms of the respective agreements.

Key Dates

Keywords

SEC filing, 8-K, Annual Meeting, stockholders, corporate governance, reverse stock split, warrants, share issuance, Nasdaq listing, dilution, biotechnology, pharmaceuticals, Dermata Therapeutics